Research Area
Host restriction to viral infection and viral countermeasures; Viral cell-to-cell transmission Innate/adaptive immunity and sensing to viral infection; Mechanisms of viral membrane fusion and entry; Cell signaling, viral oncogenes, and human lung cancer; Model viruses of study – HIV, Ebola virus, SARS-CoV-2, Influenza A virus, Zika virus, hepatitis C virus
Team Description
Team studies virus-host interactions, in particular how RNA viruses enter host cells and cause pathogenesis in humans and animals. While in the past the Liu lab has been mainly focusing on retroviruses, including HIV, current efforts also include some new human emerging and re-emerging infectious diseases, such as Ebola, Zika and COVID-19 to gain a better understanding of the molecular process by which RNA viruses enter host cells or fuse with them, as well as developing effective ways to deliver human gene therapy. The Liu lab also studies some interferon-stimulated genes (ISGs), including IFITM, LY6E, SERINC, TIM, Viperin and Tetherin, with an ultimate goal of developing effective therapeutic strategies. Another aspect of Liu lab research is viral oncology, with major efforts in elucidating how some viral oncogenes induce oncogenic transformation leading to cancer as well as discovering new tumor viruses that could be associated with human lung and other epithelial cancers.
Team Members
Team Show
Publications
1. Qu, P, J. Faraone, J. P. Evans, Y.M. Zheng, J. C. Carlin, M. Anghelina, P. Stevens, S. Fernandez, D. Jones, A. Panchal, L. J. Saif, E. M. Oltz, B. Zhang, T. Zhou, K. Xu, R.J. Gumina, and S.-L. Liu*. 2023. Enhanced Evasion of Neutralizing Antibody Response to Omicron XBB.1.5, CH.1.1 and CA.3.1 Subvariants. Cell Reports 42, 11244
2. Qu, P, J. P. Evans, C. Kurhade, C. Zeng，Y.-M. Zheng, K. Xu, P.-Y. Shi, X. Xie, and S.-L. Liu*. 2023. Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants. mBio. e03176-22.
3. Faraone, J., Qu, P, J. P. Evans, Y.-M. Zheng, J. C. Carlin, M. Anghelina, P. Stevens, S. Fernandez, D. Jones, G. Lozanski, A. Panchal, L. J. Saif, E. M. Oltz1, R.J. Gumina, and S.-L. Liu*. 2023. Enhanced Neutralization Resistance of SARS-CoV-2 Omicron XBB, BR.2 and BA.2.3.20 Subvariants. Cell Reports Medicine. 4(5):101049.
4. Xu, J, Y. Zhang, P. Qu, M. M. Shamseldi, S. Yoo, J. Misny, I. Thongpan, M. KC, J. M. Hall, J. P. Evans, M. Eltobgy, M. Lu, C. Ye, M. Chamblee, X. Liang, L. Martinez-Sobrido, A. Amer, J. Yount, P. N Boyaka, M. E. Peeples, S.-L. Liu, P. Dubey, J. Li. 2023. A next generation trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern. PNAS. In Revision.
5. Hersi, F, A. Sebastian, V. Srinivasulu, A. Mostafa, A. K. Allayeh, C. Zeng, I. Y. Hachim, D. M. Zaher, S.-L. Liu, H. A. Omara, and T. H. Al-Tel. 2023. Discovery of First-in-Class Lead Drug Candidates for Potential Treatment of COVID-19: Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19. European Journal of Medicinal Chemistry Reports. 254:115380.
6. Brown, G. Gunsch, K. Corps, S. Chaiwatpongsakorn, M. KC, M. Lu, R. Deora, M.E. Peeples, J. Li, K. Oestreich, S.-L. Liu, J. Yount, and P. Dubey. 2023. A BcfA-adjuvanted Subunit Vaccine Elicits Systemic and Mucosal Immunity in Mice that Prevents SARS CoV-2 Disease and Respiratory Pathology. J Immunol. In Press.
7. Qu, P, J. P. Evans, J. Faraone, Y.-M. Zheng, C. Carlin, M. Anghelina, P. Stevens, S. Fernandez, D. Jones, G. Lozanski, A. Panchal, L. J. Saif, E. M. Oltz1, K. Xu, R.J. Gumina, and S.-L. Liu*. 2022. Enhanced Neutralization Resistance of SARS-CoV-2 Omicron BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2 Subvariants. Cell Host & Microbe. 31(1):9-17.e3.
8. Qu, P, J. P. Evans, Y.-M. Zheng, C. Carlin, L. J. Saif, E. M. Oltz, K. Xu, R. J. Gumina, and S.-L. Liu. * 2022. Evasion of Neutralizing Antibody Responses of the SARS-CoV-2 Omicron BA.2.75 Variants. Cell Host & Microbe. S1931-3128(22)00471-1.
9. Qu, P, J. Faraone, J. P. Evans, Y.-M. Zheng, C. Carlin, J. S. Bednash, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, R. J. Gumina, and S.-L. Liu. * 2022. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. New England Journal of Medicine. 386: 2526-2528.
10. Qu, P, J. Faraone, J. P. Evans, Y.-M. Zheng, L. Yu, Q. Ma, C. Carlin, G. Lozanski, L. J. Saif, E. M. Oltz, R. J. Gumina, and S.-L. Liu. * 2022. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.4/5 and BA.2.12.1 Subvariants. New England Journal of Medicine. 387(14):1329-1331.
11. Evans, J. P, P. Qu, C. Zeng, Y.-M. Zheng, C. Carlin, J. S. Bednash, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, R. J. Gumina, and S.-L. Liu. * 2022. Neutralization of SARS-CoV-2 Deltacron and BA.3 Variants. New England Journal of Medicine. 386: 2340-2342.
12. Evans, J. P, C. Zeng, P. Qu, J. Faraone, Y.-M. Zheng, C. Carlin, J. S. Bednash, T. Zhou, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, K. Xu, R. J. Gumina, and S.-L. Liu. * 2022. Neutralization of SARS-CoV-2 Omicron Sub-lineages BA.1, BA.1.1 and BA.2. Cell Host & Microbe. S1931-3128(22)00220-7.
13. Cui, Z, C. Zeng, F. Huang, F. Yuan, J. Yan, Y. Zhao, J. Huang, H. F. Staats, Jeffrey I. Everitt, G. D. Sempowski, H. Wang1, Y. Dong*, S.-L. Liu*, and Q. Wang*. 2022. Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. Nature Chemical Biology. doi: 10.1038/s41589-022-01094-4.
14. Tang, J., C. Zeng, T. M. Cox, C. Li, Y. M. Son, I. S. Cheon, Y. Wu, S. Behl, J. J. Taylor, R. Chakaraborty, A. J. Johnson, D. N Shiavo, J. P. Utz, J. S. Reisenauer, D. E. Midthun, J. J. Mullon, E. S. Edell, M. G. Alameh, L. Borish, M. H. Kaplan, D. Weissman, R. Kern, H. Hu, R. Vassallo, S.-L. Liu*, and J. Sun*. 2022. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. Science Immunology. Oct 28, 2022. (76):eadd4853 doi: 10.1126/sciimmunol.add4853.
15. Azar, J., J. P. Evans, M. Sikorski, K. Chakravarthy, S. McKenney, I. Carmody, C. Zeng, R. Teodorescu, N. J. Song, J. Hamon, D. Bucci, M. Velegraki, C. Bolyard, K. P. Weller, S. Reisinger, S. A. Bhat, K. J. Maddocks, R. J. Gumina, A. N. Vlasova, E. M. Oltz, L. J. Saif, D. Chung, J. A. Woyach, P. G. Shields, S.-L. Liu*, Z. Li*, M. P. Rubinstein*. 2023. Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI Insight. 8(6):e163434.
16. Shamseldin, M. M, A. Zani, A. Kenney, J. Evans, C. Zeng, K. Read, K. Caution, J.M. Hall, J.
17. Blawut, B, B. Wolfe, C. Premanandanc, G. Schuenemann, S. A. Ludsind, S.-L. Liu, D. N. R. Veeramachaneni, and M. A. C. da Silva. Effects of activation and assisted reproduction techniques on the composition, structure, and properties of the sauger (Sander Canadensis) spermatozoa plasma membrane. 2022. Theriogenology. 198: 87-99.
18. Abdelhamid, A. G, J. N. Faraone, J. P. Evans, S.-L. Liu, and A. E. Yousef. 2022. SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. Pathogens. July 27, 2022. doi.org/10.3390/pathogens11080837.
19. Karger, A., B, J. D. Brien, J. M. Christen, S. Dhakal, T. J. Kemp, S. L. Klein, L. A. Pinto, L. Premkumar, J. D. Roback, R. A. Binder, K. W. Boehme, S. Boppana, J. M. Crawford, J. L. Daiss, A. P. Dupuis II, A. M. Espino, C. Forconi, J. C. Forrest, R. C. Girardin, N. S. Haddad, C. D. Heaney, D. T. Hunt, J. L. Kennedy, C. L. King, K. Kruczynski, J. LaBaer, F. E.-H. Lee, W. T. Lee, S.-L. Liu, G. Lozanski, A. M. Moormann, V. Murugan, N. Okoye, P. Pantoja, A. F. Payne, J. Park, S. Pinninti, A. K. Pinto, N. Pisanic, J. Qiu, C. A. Sariol, L. Song, T. L. Steffen, E. T. Stone, L. M. Styer, M. S. Suthar, S. N. Thomas, B. Thyagarajan, J. L. Yates, and K. Sobhani. 2022. The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. mSphere. Jun 15: e0019322.
20. Zeng, C, J. P. Evans, P. Qu, J. Faraone, Y.-M. Zheng, C. Carlin, J. S. Bednash, T. Zhou, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, K. Xu, R. J. Gumina, and S.-L. Liu. * 2022. Neutralization and Stability of SARS-CoV-2 Omicron Variant. bioRxiv. 2021 Dec 20:2021.12.16.472934. doi: 10.1101/2021.12.16.472934.
21. Evans, J. P., C. Zeng, C. Carlin, G. Lozanski, L. J. Saif, E. M. Oltz, R. J. Gumina, and S.-L. Liu*. 2022. Neutralizing Antibody Responses Elicited by SARS-CoV-2 mRNA Vaccination Wane Over Time and are Boosted by Breakthrough Infection. Sci Transl Med. 14 (637): eabn8057.
22. Zeng C, J.P., Evans, K. Chakravarthy, P. Qu, S. Reisinger, N.-J. Song N, M.P. Rubinstein M, P.G. Shields, Z. Li Z, and S.-L. Liu*. 2022. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. Dec 30: S1535-6108(21)00688-7.
23. Gyang, TC*, J. P. Evans, J. Miller, K. Alcorn, J. Peng, E. Bell, C. Zeng, R. J. Gumina, B. Segal, and S.-L. Liu*. 2022. Efficacy of SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis. Multiple Sclerosis Journal—Experimental, Translational and Clinical. 8(1): 20552173221087357. 2022 Mar 22;8(1):20552173221087357.
24. Zeng C, J. P., Evans JP, T, King, Y.-M. Zheng, E. M., Oltz, S. P. J, Whelan, L. J. Saif, M. E., Peeples ME, and S.-L. Liu*. 2021. SARS-CoV-2 Spreads through Cell-to-Cell Transmission. Proc. Natl. Acad. Sci. USA. 119(1): e2111400119.
25. Zeng, C, J. P. Evans, J. N. Faraone, P. Qu, Y.-M. Zheng, L. J. Saif, E. M. Otlz, G. Lozanski, R. J. Gumina and S.-L. Liu*. 2021. Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H. mBio. 12(5): e0251021.
26. Zeng, C, A. A. Waheed, T. Li, J. Yu, Y.-M. Zheng, J. Yount, H. Wen, E.O. Freed, and S.-L. Liu*. 2021. SERINC Proteins Potentiate Antiviral Type I IFN Induction and Proinflammatory Signaling Pathways. Science Signaling 14: eabc7611, Sept 14.
27. Zeng, C, J. P. Evans, S. Reisinger, J. Woyach, C. Liscynesky, Z. E. Boghdadly, M. P. Rubinstein, K. Chakravarthy, L. Saif, E. M. Oltz, R. J. Gumina, *Peter G. Shields, Z. Li*, and S.-L. Liu*. 2021. Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccine in Cancer Patients. Cell & Bioscience. 11(1):197.
28. Song, N-J, C. Allen, A. E. Vilgelm, B. P. Riesenberg, K. P. Weller, K. Reynolds, K. B. Chakravarthy, A. Kumar, A. Khatiwada, Z. Sun, A. Ma, Y. Chang, M. Yusuf, A. Li, C. Zeng, J. P. Evans, D. Bucci, M. Gunasena, M. Xu, N. P.M. Liyanage, C. Bolyard, M. Velegraki, S.-L. Liu, Q. Ma, M. Devenport, Y. Liu, P. Zheng, C. D. Malvestutto, D. Chung, and Z Li. 2022. Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology. J Hematol Oncol. 15 (1): 5.
29. Lu, M, P. Dravid, Y. Zhang, S. Trivedi, A. Li, O. Harder, K.C. Mahesh, S. Chaiwatpongsakorn, A. Zani, A. Kenney, C. Zeng, C. Cai, C. Ye, X. Liang, M. Shimamura, S.-L. Liu, P. N Boyaka, J. Qiu, L. Martinez-Sobrido, J. Yount, M. Peeples, Kapoor, S. Niewiesk, and J. Li. 2021. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc. Natl. Acad. Sci. USA. Mar 23;118(12): e2026153118.
30. Evans, J. P, and S.-L. Liu*. 2021. Role of host factors in SARS-CoV-2 Entry. J. Biol. Chem. 297(1):100847.
31. Kim, E, Z. Attia, R. M. Woodfint, C.Zeng, S. Kim, H. E. Steiner, R. K. Shukla, N. P. M. Liyanage, J. Li, G. J. Renukaradhya, A. A. Satoskar, A. O. Amer, S.-L. Liu, E. Cormet-Boyaka, and P. N. Boyaka. 2021. Inhibition of elastase enhances the adjuvanticity of alum and promotes anti–SARS-CoV-2 systemic and mucosal immunity. Proc. Natl. Acad. Sci. USA. 118 (34) e2102435118.
32. Zhao, A. A, Z. Su, R., Komissarov, S.-L. Liu, G, Yi, S. Idell, M. A. Matthay & H.-L. Ji. 2021. Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression. Front Immunol 7;12:691249.
33. Lu M, Y. Zhang, P. Dravid, A. Li, C. Zeng, K C Mahesh, S. Trivedi, H. Sharma, S. Chaiwatpongsakorn, A. Zani, A. Kenney, C. Cai, C. Ye, X. Liang, J. Qiu, L. Martinez-Sobrido, J. S. Yount, P. N. Boyaka, S.-L. Liu, M. E. Peeples, A. Kapoor, J. Li J. 2021. A methyltransferase-defective VSV-based SARS-CoV-2 vaccine candidate provides complete protection against SARS-CoV-2 infection in hamsters. J. Virol. doi: 10.1128/JVI.00592-21
34. Zeng, C, J. P. Evans, R. Pearson, P. Qu, Y.-M. Zheng, R. T. Robinson, L. Hall-Stoodley, J. Yount, S. Pannu, R. K. Mallampalli, L. Saif, E. Oltz, G. Lozanski, and S.-L. Liu*. 2020. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors. JCI Insight. 5(22): e143213.
35. Wu, Y, W. Ho, Y. Huang, D.-Y. Jin, S. Li, S.-L. Liu, X. Liu, J, Qiu, Y. Sang, Q. Wang, K.-Y. Yuen, and Z.-M. Zheng. 2020. SARS-CoV-2 is an appropriate name for the new coronavirus. The Lancet 395 (10228): 949-950.
36. Liu, S.-L.*, L. Saif, S. R. Weiss, and L. Su*. 2020. No Credible Evidence Supporting Claims of the Laboratory Engineering of SARS-CoV-2. Emerg. Microbes & Infect. 9(1):505-507. doi: 10.1080/22221751.2020.1733440.
37. Liu, S.-L*. New Virus in China Requires International Control Effort. 2020. Nature 577(7791): 472.
38. Liu, S.-L.*, and L. Saif. 2020. Emerging Viruses without Borders: The Wuhan Coronavirus.Viruses. 12(2). pii: E130. doi: 10.3390/v12020130.